According to the latest documents disclosed by the US SEC, up to 13.6 million ordinary shares of Ping An Biomedical Co., Ltd. will be resold by its selling shareholders.

This resale plan involves a large number of shares and is expected to have a certain impact on the company's equity structure. Market analysts point out that such shareholder reduction actions usually draw investors' attention to the company's future development prospects. The document does not disclose the specific identities of the shareholders reducing their holdings or the timetable for the reduction. The company has not yet made further comments regarding this share resale matter.